Similar articles

• Long-term outcomes of pre-emptive valganciclovir compared with valacyclovir prophylaxis for prevention of cytomegalovirus in renal transplantation.

  Reischig T, Hribova P, Jindra P, Hes O, Bouda M, Treska V, Viklicky O. Reischig T, et al. J Am Soc Nephrol. 2012 Sep;23(9):1588-97. doi: 10.1681/ASN.2012010100. Epub 2012 Aug 23. J Am Soc Nephrol. 2012. PMID: 22917575 Free PMC article. Clinical Trial.
• Anti-cytomegalovirus prophylaxis in solid-organ transplant recipients.

  Falagas ME, Vardakas KZ. Falagas ME, et al. Clin Microbiol Infect. 2006 Jul;12(7):603-5. doi: 10.1111/j.1469-0691.2006.01405.x. Clin Microbiol Infect. 2006. PMID: 16774555
• Valganciclovir versus valaciclovir for prevention of alemtuzumab-induced cytomegalovirus reactivation: what are the implications for routine clinical practice?

  Smolej L. Smolej L. Blood. 2008 Sep 1;112(5):2167. doi: 10.1182/blood-2008-05-155465. Blood. 2008. PMID: 18725576 No abstract available.
• Advances in cytomegalovirus-preventive strategies in solid organ transplantation: defending pre-emptive therapy.

  Reischig T. Reischig T. Expert Rev Anti Infect Ther. 2012 Jan;10(1):51-61. doi: 10.1586/eri.11.156. Expert Rev Anti Infect Ther. 2012. PMID: 22149614 Review.
• Prophylaxis of cytomegalovirus infection in renal transplantation: new data for an old problem.

  Kuypers DR, Vanrenterghem YF. Kuypers DR, et al. Nephrol Dial Transplant. 1999 Oct;14(10):2304-8. doi: 10.1093/ndt/14.10.2304. Nephrol Dial Transplant. 1999. PMID: 10528649 Review. No abstract available.